Francesca Pavesi

Busto Arsizio, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.

Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.

Journal: Haematologica
Published: March 16, 2026

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.

Journal: Haematologica
Published: December 03, 2025

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Journal: British journal of haematology
Published: July 29, 2025

miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.

miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.

Journal: Leukemia
Published: March 14, 2023

Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia.

Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia.

Journal: Nature communications
Published: December 16, 2021

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up.

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up.

Journal: HemaSphere
Published: May 16, 2021

Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.

Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.

Journal: Leukemia research
Published: May 01, 2021

Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.

Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.

Journal: Transplantation and cellular therapy
Published: February 07, 2021

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

Journal: Blood cancer journal
Published: May 23, 2020

The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.

The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.

Journal: International journal of antimicrobial agents
Published: March 13, 2020

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Journal: Nature communications
Published: December 14, 2016

Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).

Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).

Journal: Annals of hematology
Published: April 17, 2016
Showing 1-12 of 14

Last Updated: 09/26/2026